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Abstract
Ptp4a3 (commonly known as PRL-3) is an enigmatic member of the Ptp4a family of prenylated protein tyrosine
phosphatases that are highly expressed in many human cancers. Despite strong correlations with tumor metastasis and
poor patient prognosis, there is very limited understanding of this gene family’s role in malignancy. Therefore, we created a
gene-targeted murine knockout model for Ptp4a3, the most widely studied Ptp4a family member. Mice deficient for Ptp4a3
were grossly normal. Fewer homozygous-null males were observed at weaning, however, and they maintained a decreased
body mass. Although Ptp4a3 is normally associated with late-stage cancer and metastasis, we observed increased Ptp4a3
expression in the colon of wildtype mice immediately following treatment with the carcinogen azoxymethane. To
investigate the role of Ptp4a3 in malignancy, we used the most commonly studied murine colitis-associated colon cancer
model. Wildtype mice treated with azoxymethane and dextran sodium sulfate developed approximately 7–10 tumors per
mouse in the distal colon. The resulting tumor tissue had 4-fold more Ptp4a3 mRNA relative to normal colon epithelium and
increased PTP4A3 protein. Ptp4a3-null mice developed 50% fewer colon tumors than wildtype mice after exposure to
azoxymethane and dextran sodium sulfate. Tumors from the Ptp4a3-null mice had elevated levels of both IGF1Rb and c-
MYC compared to tumors replete with Ptp4a3, suggesting an enhanced cell signaling pathway engagement in the absence
of the phosphatase. These results provide the first definitive evidence implicating Ptp4a3 in colon tumorigenesis and
highlight the potential value of the phosphatase as a therapeutic target for early stage malignant disease.
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Introduction
Protein tyrosine phosphatase-4a3 (Ptp4a3), along with Ptp4a1
and Ptp4a2, comprise the 4a-family of protein tyrosine phospha-
tases. This modest gene family is commonly referred to as the
phosphatases of regenerating liver (PRL), due to the discovery of
Ptp4a1 in the regenerating liver cells of mice following partial
hepatectomy [1]. The significant homology (.75% amino acid
identity) found among Ptp4a family members may denote similar
enzymology but all three family members are conserved through-
out mammalian species, suggesting non-redundant biological roles
for each. The in vivo properties and functions of these enigmatic
phosphatases remain remarkably poorly understood.
Interest in Ptp4a3 can be attributed to its significant potential as
a biomarker and as a therapeutic target for malignant cancers.
Many human cancers express high PTP4A3 levels including
tumors of the colon [2], breast [3], ovary [4], liver [5], stomach
[6], and stroma [7], and elevated PTP4A3 expression often
correlates with increased tumor invasiveness and poor prognosis
[8]. Additionally, ectopic PTP4A3 overexpression enhances tumor
cell migration and invasion in vitro [9]. While definitive evidence is
lacking, Ptp4a3 has been proposed to modulate multiple signaling
pathways involving SRC [10], Rho GTPases [9], and PI3K-Akt
[11] in various forms of cancer. The complexity of the pathway
alterations seen when Ptp4a3 is overexpressed may also reflect its
ability to act as a phosphatidylinositol 5-phosphatase [12]. No
reports have conclusively demonstrated a role for Ptp4a3 in the
physiology of normal cells or tissues.
Azoxymethane (AOM) is a procarcinogen that when metabo-
lized in the colon is mutagenic and drives tumorigenesis. AOM in
combination with the inflammatory agent dextran sodium sulfate
(DSS) produces a widely-used murine model that faithfully
replicates colon malignancies driven by chronic inflammatory
conditions such as ulcerative colitis [13]. Several signaling
pathways are implicated in the pathogenesis of AOM-induced
colon cancer including KRAS [14], b-Catenin [15], c-MYC [16],
Insulin-like Growth Factor-1 Receptor b (IGF1Rb) [17], and
Transforming Growth Factor b (TGFb) [18]. Interestingly, Ptp4a3
has been identified as a direct regulatory target of TGFb signaling
in colon cancer [19].
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In the current study, we used a gene-targeting approach to
generate mice lacking Ptp4a3 and interrogate the potential role of
Ptp4a3 in colon tumorigenesis. AOM exposure acutely increased
Ptp4a3 expression in the colon. Ptp4a3-null mice were resistant to
colon tumorigenesis implicating this gene in the pathogenesis of
malignant disease. Moreover, tumors derived from Ptp4a3-null
mice overexpresssed the cancer associated IGF1Rb and c-MYC
suggesting involvement of these oncogenic signaling pathways.
Figure 1. Gene-targeting the Ptp4a3 locus. A) The Ptp4a3 floxed allele was created by inserting loxP sites (red arrowheads) around exon 2. This
mutation resulted in the disruption of a HindIII sequence that increases the size of the DNA fragment produced by restriction digest from 5.6 to
10.2 kb. Following expression of Cre recombinase, the sequence between the loxP sites is removed leaving a single loxP site and decreasing the size
of the restriction fragment to 6.4 kb. This mutation results in deletion of the initiation codon causing a frameshift mutation producing a
nonfunctional protein product. B) Southern blot analysis of genomic DNA was used to monitor these genetic changes and genotype mice containing
the wildtype, floxed, or knockout alleles. Each lane is from an individual mouse. C) Quantitative RT-PCR analysis on total mRNA from fetal heart tissue
revealed no change in Ptp4a1 and Ptp4a2 mRNA levels while Ptp4a3 was reduced and not detectable in heterozygous and homozygous-null tissue,
respectively. (* = p,0.05; n = 4/genotype). D) The PTP4A3 protein product was detectable by western blot in whole protein lysates from wildtype and
heterozygous fetal heart tissue, but not in homozygous Ptp4a3-null samples.
doi:10.1371/journal.pone.0058300.g001
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Results
Creation of Ptp4a3 mutant mice
We disrupted the Ptp4a3 genomic locus using the Cre-lox system
of site-specific recombination based on the position of two inserted
loxP sites (Fig. 1A and further detail in Fig. S1). Mutant mice were
backcrossed to the C57BL/6J strain for at least five generations.
The knockout allele was created by crossing Ptp4a3-floxed mice
with transgenic mice expressing CRE-recombinase driven from a
general promoter (EIIA) to recombine the target site and create
global knockout mice [20]. Insertion of the 39 loxP site destroyed
an endogenous HindIII site increasing the size of the genomic
DNA fragment produced by restriction digest from 5.6 to 10.2 kb.
Subsequent deletion of the target sequence reduced the restriction
fragment size from 10.2 to 6.4 kb. Distinct band sizes correspond-
ing to each allele are observed when analyzed by Southern blot
hybridization with a ,300 bp probe corresponding to exon 6
(Fig. 1B).
An analysis of .500 pups that were produced by heterozygous
mating pairs indicated all potential genotypes were observed in the
resulting offspring. While females were observed at the expected
Mendelian ratios, we noted a significant decrease (p,0.05) in the
number of Ptp4a3-null males at weaning relative to the predicted
frequency (Table 1). Given this finding, it is possible that knockout
males either possessed a survival disadvantage or that Ptp4a3-null
germ cells had a preconception phenotype. Ptp4a3-null male mice
exhibited an approximate 10% decrease in body mass (p,0.003)
and 7% decrease in body mass index (p,0.004) compared to
wildtype littermates at 6 wk of age (Fig. S2). This phenotype also
appeared to be confined to male mice as female Ptp4a3-null mice
did not exhibit a significant decrease in body mass or body mass
index.
Because fetal heart tissue had been previously suggested to have
high levels of Ptp4a3 expression [21], we next performed
quantitative RT-PCR on total RNA samples from fetal heart
tissue (E19.5) to determine the relative mRNA levels of Ptp4a1,
Ptp4a2, and Ptp4a3. While Ptp4a1 and Ptp4a2 levels remained
similar between genotypes, Ptp4a3 mRNA was reduced in
heterozygous tissue and not detectable in samples from Ptp4a3-
null fetal heart tissue (Fig. 1C). Thus, compensation for Ptp4a3 loss
by upregulation of either family members Ptp4a1 or Ptp4a2 at the
mRNA level was excluded. Protein lysates from fetal heart tissue
were assayed by Western blot for the presence of the PTP4A3
protein product. While detectable in samples from wildtype
embryos, PTP4A3 was lower in lysates from heterozygous
embryos and homozygous-null tissue contained no detectable
PTP4A3 (Fig. 1D). Aside from the aforementioned phenotypic
observations, mice without functional Ptp4a3 appeared grossly
normal relative to wildtype littermates.
Expression and knockout of Ptp4a3 in mouse tissues
Because the expression of endogenous PTP4A3 protein in
normal tissues has not been well characterized, we examined tissue
protein samples from wildtype and Ptp4a3-null mice. First, we
assayed several tissue types for PTP4A3 protein expression by
Western blot (Fig. S3). Fetal heart, fetal intestine, adult heart,
skeletal muscle, pancreas, lung, spleen, brain, thymus, colon, and
small intestine all expressed detectable levels of PTP4A3 in
contrast to the liver and kidney, which had no detectable PTP4A3
protein. These results also confirm the efficacy of the global gene
deletion approach, as no PTP4A3 protein was detectable in any of
the lysates from Ptp4a3-null mice. Histological analysis was also
performed on wildtype and Ptp4a3-null tissue samples (Fig. S4).
Upon examining multiple tissue types, no overt abnormalities were
observed and all samples appeared qualitatively normal.
Ptp4a3 expression increases immediately following AOM
exposure
Since low levels of PTP4A3 were detectable in the normal colon
epithelium, we assayed Ptp4a3 gene expression immediately
following treatment with the intestinal procarcinogen AOM
(12.5 mg/kg) or saline control in wildtype C57BL/6J mice. Mice
were sacrificed 8 and 24 hr after AOM injection and colon
epithelial cells were collected for analysis. Total mRNA was
isolated and quantitative RT-PCR was performed to assay for
Ptp4a3 gene expression levels. Interestingly, Ptp4a3 was upregu-
lated by 78% at 8 hr and 60% at 24 hr in AOM-treated normal
epithelial relative to control (Fig. 2C). Protein lysates from AOM
treated mice suggest that the PTP4A3 protein levels are also
increased in these tissues (Fig. 2D). While the role of Ptp4a3 in
colon cancer is traditionally thought to involve late-stage tumors
and metastasis, this finding suggests a potential role in early-stage
disease and tumorigenesis.
Knockout of Ptp4a3 suppresses intestinal tumor
formation
To explore a potential functional role for Ptp4a3 in tumor
formation, we subjected mice to a widely used AOM-DSS model
of colitis-associated colon cancer. Wildtype and Ptp4a3 – null mice
were injected with a single dose of AOM (12.5 mg/kg) followed by
three cycles of 2.5% DSS consumption (Fig. 2A). This model
produces distinct histological changes relative to normal controls,
including inflammation corresponding to DSS treatment, and
Table 1. Genotype distribution of Ptp4a3 mutant mice.
Offspring genotype at weaning
Male +/+ +/2 2/2 n X2 p
Observed 75 117 48 240 6.23 ,0.05
Expected 60 120 60
Female +/+ +/2 2/2 n X2 p
Observed 70 127 79 276 2.34 N.S.
Expected 69 138 69
There was a observed decrease in number of male Ptp4a3-null mice observed at weaning relative to the expected amount predicted by Mendelian genetics (p,0.05).
Female mice of each genotype were born at the expected frequency (1:2:1).
doi:10.1371/journal.pone.0058300.t001
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subsequent dysplasia (Fig. 2B). Tumors were visually obvious in
the distal colon of wildtype mice upon sacrifice at 12 or 16 wk
after the initial AOM treatment and were (Fig. 2B and 3A). As
indicated in Figure 3B, Ptp4a3-null mice exhibit a 54% decrease in
tumor number (p,0.004) following 16 wk of treatment. Although
on average fewer tumors were observed at 12 wk in Ptp4a3-null
mice relative to wildtype, this was not statistically significant
(p.0.2). Interestingly, the number of tumors (p = 0.05) as well as
tumor diameter (P,0.001) was significantly increased from 12 to
16 wk, while Ptp4a3-null tumors did not significantly increase in
number or size. The average diameter of tumors produced by this
model was 3–4 mm (Fig. 3C).
Ptp4a3 is elevated in AOM-derived colon tumors
Because high expression of PTP4A3 has been reported in
human primary colon tumors [22], we examined Ptp4a3 expres-
sion in the mouse model of colon cancer. First, total mRNA was
extracted from tumor tissue from wildtype mice and quantitative
RT-PCR was used to assay for the expression level of each Ptp4a
Figure 2. Ptp4a3 is expressed in AOM-DSS derived colon tumors and normal tissue. A) The AOM-DSS treatment paradigm used in this
study features a single dose of AOM followed by 3 treatment cycles of DSS in the drinking water. B) Histological representation of normal colon tissue
relative to tumor tissue demonstrates the efficacy of the AOM-DSS model. Following one cycle of DSS treatment, crypt dysplasia and mononuclear
cell infiltration were apparent. Tumor tissue was present at both the 12 and 16 wk endpoints. Before sacrifice, mice were treated with BrdU for 4 hrs
and cell proliferation was visualized by staining with a BrdU antibody. C) Quantitative RT-PCR was used to assay Ptp4a3 gene expression in normal
colon epithelial tissue following treatment with either AOM or saline control. Ptp4a3 was elevated 73% in colon tissue following when measured 8 hr
after injection and 60% at 24 hr (* = p,0.001; n = 6/treatment group; bars = SEM). D) Western blot of colon lysates indicated an increase in PTP4A3
protein following AOM exposure. E) Quantitative RT-PCR indicated changes in gene expression levels of Ptp4a family members in normal colon and
tumor tissue. Ptp4a3 was elevated 3.7-fold (** = p,0.01), while Ptp4a1 and Ptp4a2 levels were significantly decreased (* = p,0.0001 and p,0.05,
respectively) (n = 15, bars = SEM). F) Western blot analysis demonstrating higher PTP4A3 protein levels in colon tumors compared to normal tissue.
G) Western blot combined with qRT-PCR analysis also demonstrated that when comparing Ptp4a3 mRNA levels (listed above each lane) to PTP4A3
protein, high gene expression appeared to correspond to higher protein levels.
doi:10.1371/journal.pone.0058300.g002
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family member (Fig. 2E). Relative to normal colon epithelium,
Ptp4a3 was elevated 3.7-fold on average (p,0.01). While
considerable heterogeneity in Ptp4a3 expression was observed,
ranging from 1.4 to 6.7-fold upregulation, Ptp4a3 mRNA levels in
tumor tissue were consistently higher than normal tissue for every
sample tested (n = 15). Interestingly, the gene expression levels of
Ptp4a1 and Ptp4a2 were both downregulated 64% and 36%
(p,0.0001 and p,0.05), respectively, in colon tumors relative to
normal tissue. PTP4A3 protein levels in normal colon epithelial
lysates were very low when assayed by Western blotting (Fig. 2F).
In contrast, PTP4A3 was readily detectable, but variable, in colon
tumor samples. As might be expected, there appeared to be some
correlation between the PTP4A3 protein levels and the mRNA
levels (Fig. 2G). The lack of functional antibodies for PTP4A1 and
PTP4A2 precluded evaluating the tumor protein levels for these
family members.
Loss of Ptp4a3 increases IGF1Rb and c-MYC expression in
tumors
We next examined lysates obtained from both wildtype and
Ptp4a3-null colon tumors. We first used reverse phase protein
array to assay the levels of over 130 different protein products
contained in wildtype and Ptp4a3-null tumors (Fig. S5). While
protein levels in these tumors exhibited considerable heterogene-
ity, two known oncogenic signaling proteins, the receptor tyrosine
kinase IFG1Rb and the transcription factor c-MYC were
expressed at higher levels in Ptp4a3-null tumors (Fig. 4A).
Following quantification, IGF1Rb protein was on average 2.1-
fold higher (p,0.001) and c-MYC was about 2.5-fold higher
(p,0.02) in Ptp4a3-null relative to wildtype colon tumors (Fig. 4B–
C). In contrast, we did not observe a significant difference in AKT
activation between genotypes (Fig. 4D). This result suggests that
tumors can potentially compensate for Ptp4a3 deficiency though
altered signaling pathways.
Discussion
A number of genes have been implicated in the development
and progression of colorectal cancer. Previous gene expression
profiling studies identified 144 genes that are up-regulated in
metastatic colorectal liver samples [2]. The only gene, however,
that was consistently elevated in all of the metastatic samples was
Ptp4a3. Both gene amplification and enhanced transcriptional
activity are likely causal for the high levels. Despite the apparent
importance of Ptp4a3 in tumor biology, our understanding of the
functionality of Ptp4a3 is severally limited due in part to the
absence of informative animal models. The gene targeted mouse
model for disruption of the Ptp4a3 genomic locus that we have
developed is useful not only for studying the phenotypic changes
that occur with the global loss of the phosphatase, but also for
future investigations on tissue and temporal specific gene deletion
and collaborative interactions with other genes including the two
other members of the Ptp4a family. Our model establishes that
mice can survive in the absence of a functional Ptp4a3 gene,
although there were a slightly lower number of male mice
produced, and they are able to live to maturity under normal
conditions without any major health deficiencies. This is in
contrast to what has been reported with mice lacking the highly
homologous Ptp4a2, which is thought to be the most ubiquitously
expressed family member under normal conditions. Ptp4a2-null
mice exhibited defective placental development and both genders
showed retarded growth at embryonic and adult stages [23].
Ptp4a2 loss decreases the spongiotrophoblast and decidua layers of
the placenta impairing nutrient transport and causing embryonic
growth retardation. Moreover, loss of Ptp4a2 results in AKT
inactivation, which was not evident in our data regarding Ptp4a3
loss. Collectively, the differences in the two gene deletion models
are consistent with non-overlapping functions of these two close
phosphatase family members.
Deletion of PTP4A3 protein was confirmed by Western blot
analysis using a variety of tissue lysates from wildtype and Ptp4a3-
null mice. Although initial studies had suggested Ptp4a3 expression
was restricted to heart, skeletal muscle, and pancreas [24], our
data revealed a more ubiquitous expression pattern. While the
highest levels of PTP4A3 were observed in fetal heart, the protein
was also detectable at lower levels in adult heart, skeletal muscle,
spleen, pancreas, brain, lung, thymus, colon, and small intestine;
no PTP4A3 protein was detectable the liver or kidney.
Because human PTP4A3 is been implicated in the pathogenesis
of human metastatic colorectal cancer, we investigated the effects
of Ptp4a3 deletion in a mouse model of colon cancer. Treatment
Figure 3. Ptp4a3 knockout suppresses colon tumor formation.
A) Image depicting the appearance of wildtype and Ptp4a3-null colon
tissue following 16 wk treatment with AOM-DSS. B) The average
number of tumors was recorded in mice by genotype after 12 and
16 wk of treatment. The average number of tumors significantly
increased in wildtype mice between the 12 to 16 wk time points
(* = p= 0.05). During this time the number of tumors observed in
Ptp4a3-null mice was the same (p = 0.70). At 12 wks, wildtype mice
(n = 6) did not have significantly more tumors per mouse than Ptp4a3-
null (n = 5) mice (p = 0.27). At 16 wk, wildtype mice (n = 14) displayed
significantly less tumors per mouse than Ptp4a3-null mice (n = 7)
(** = p,0.005). C) Tumor size (measured by average tumor diameter for
each mouse) was determined at each time point. Tumor diameter was
observed to significantly increase in wildtype mice from 12 to 16 wks
(* = p,0.001). No significant difference was observed in Ptp4a3-null
mice from 12 to 16 wks, or between genotypes at either time point.
Bars = SEM.
doi:10.1371/journal.pone.0058300.g003
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with AOM/DSS is one of the most popular colon tumor mouse
models and the C57BL/6J strain to which this model was
backcrossed is particularly susceptible to colitis-associated cancer
[13,16,17]. Ptp4a3 is traditionally classified as a gene associated
with metastasis and not known to be involved in the early stages of
cancer progression. In the current study, we provide evidence that
the Ptp4a3 mRNA and PTP4A3 protein levels are increased soon
after exposure to AOM, the initiating step in our colon cancer
model. This is important evidence that PTP4A3 could be also
involved in the preneoplastic stage of malignancy.
Mice subjected to the AOM/DSS model consistently developed
tumors in the distal region of the colon. These primary tumors
displayed consistently higher levels of Ptp4a3 relative to normal
colon epithelium – similar to what is seen in human colon cancer
patients [22]. Notably, mice deficient for Ptp4a3 had .50%
reduction in tumor formation providing further evidence that
Ptp4a3 is a key mediator of colon cancer progression. Nevertheless,
the complete absence of PTP4A3 phosphatase was insufficient to
abolish colon tumorigenesis, suggesting that a subset of tumors
may not require Ptp4a3 as a driver of the disease. This is supported
by the finding that not all tumors in this model had high (.2-fold
upregulation) Ptp4a3 expression levels.
The animal model we have developed presents a unique
opportunity to address the role of Ptp4a3 in tumor biology. AOM
exposure causes DNA damage and genotoxic stress. A prominent
response to DNA damage is induction of p53, which can induce
Ptp4a3 expression [25] and may provide an explanation for the
induction of Ptp4a3 in the colon of AOM treated mice.
Additionally, Ptp4a3 has been identified as a direct regulatory
target of TGFb signaling in colon cancer cells. The active TGFb
signal induces SMAD3/4 binding to the Ptp4a3 genomic locus and
thus inhibition of gene transcription [19]. Loss of TGFb is a
frequently observed phenomenon in human colon cancer [26], as
well as the AOM mouse model of colon cancer [18]. It is likely that
this event contributes to elevated Ptp4a3 gene expression in cancer
through SMAD3/4 inactivation. Interestingly, a mouse model
deficient for Smad3 has been reported to spontaneously develop
colon cancer [27], and Smad4 deficiency greatly exacerbates a
mouse model of colon cancer [28]. The formation of neoplastic
lesions in the Ptp4a3-null mice may be the consequence of the
engagement of additional growth factor signaling pathways or
oncogenes, such as IFG1Rb and c-MYC. c-MYC is known to be
increased in tumors after AOM/DSS treatment and both IFG1Rb
and c-MYC were markedly elevated in the Ptp4a3-null tumors
relative to wildtype derived tumors.
Figure 4. Higher IGF1Rb and c-MYC levels in Ptp4a3-null tumors. A) Cluster sample of the heatmap generated from RPPA analysis that was
performed using colon tumor lysates from AOM-DSS treated wildtype and Ptp4a3-null mice. Protein targets were either higher (yellow), lower (blue),
or unchanged (black). B) Protein levels were confirmed by western blot analysis colon tumor lysates from wildtype and Ptp4a3-null mice. IGF1Rb and
c-MYC protein were chosen because of they appeared to be the most consistently upregulated proteins in Ptp4a3-null samples. C) When quantified,
IGFIRb protein levels were 2.1-fold higher in Ptp4a3-null tumors (p,0.001). D) c-MYC protein levels were 2.5-fold higher in Ptp4a3-null tumors
(p,0.02). E) The levels of activated AKT, as indicated by phosphorylation of Ser473, were not significantly different by genotype relative to total AKT
protein.
doi:10.1371/journal.pone.0058300.g004
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While the Ptp4a3 gene product initially was thought to be
involved in tumor metastasis and late stage disease, our results
provide evidence for possible roles at other stages of the disease
including pre-neoplastic transformation and early carcinogenesis.
The concept of therapeutically targeting Ptp4a3 could, therefore,
be attractive at multiple stages of cancer.
Materials and Methods
Creation of Ptp4a3 mutant mice
The conditional gene-targeting vector was constructed using a
phage-based E. coli recombination system [29]. Specific details
regarding the vector construction and targeting strategy are
described in Fig. S1. We specifically targeted exon 2 because it
contained the transcriptional start site and was necessary for
proper translation of the mRNA transcript. Following transfection
of the construct into R1 embryonic stem cells [30], mice were
created from correctly targeted clones using standard chimeric
animal production techniques with C57BL/6J blastocysts. The
novel strain was backcrossed to C57BL/6J (The Jackson
Laboratory) for .5 generations and mice for experiments were
produced using heterozygous breeding pairs. Genotyping was
performed by Southern blot analysis with a radiolabeled probe
corresponding to ,300 bp of exon 6, which was external to the
gene targeting vector. This study was carried out in accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
relevant protocols were approved by the Institutional Animal Care
and Use Committee of the University of Pittsburgh.
AOM cancer model
Wildtype and Ptp4a3-null mice (male, 6–8 wks) were adminis-
tered a single dose of AOM (12.5 mg/kg) (Sigma) in sterile saline
by IP injection. DSS solution (2.5%) (MP Biomedicals) was given
ad libitum for 7 d followed by 14 d of normal drinking water and
this cycle was repeated a total of 3 times [13]. Experimental mice
were euthanized at 12 or 16 wk following the initiation of
treatment, at which point colon tissue was isolated, rinsed, and
opened longitudinally for analysis. Tumor and normal tissue were
either snap frozen in liquid nitrogen or submerged in 10% neutral
buffered formalin. For each mouse, individual tumors were
counted and measured with a digital caliper and average tumor
count and diameter were determined for each genotype.
Western blot analysis
Cells and tissues were lysed using RIPA buffer and quantified by
Bradford assay. A total protein sample of 40 mg was separated
using Novex SDS-PAGE reagents (Invitrogen) and transferred to
nitrocellulose membranes. Membranes were blocked in Odyssey
buffer (LiCor Biosciences) and incubated with primary antibodies
overnight followed by secondary fluorescent antibodies according
to the manufacturers’ instructions. We used the following
commercially available primary antibodies: PTP4A3 clone 318
(Santa Cruz Biotechnology), GAPDH, IGF1Rb, c-MYC, p-
AKT(S473), and AKT (Cell Signaling Technology).
Quantitative RT-PCR
Total RNA was extracted from tissue using Trizol reagent as
per the manufacturer’s protocol (Invitrogen). A total of 500 ng of
mRNA was converted to cDNA using the iScript first strand
synthesis kit (Bio-Rad). The primers (Tab. S1) used for target
amplification were diluted to a final concentration of 500 pM, and
real-time monitoring of the PCR reaction was performed on a
Biorad iQ5 thermocycler with 2X Sybr Green Mastermix (Bio-
Rad). The following program was run for 40 cycles: 95uC for 0:30;
58uC for 1:00; and 72uC for 0:30.
Reverse phase protein array
Protein lysates (100 ug each) from colon tumor samples (n = 5/
genotype) were denatured and shipped frozen to MD Anderson
Cancer Center (Houston, TX) for analysis. Briefly, lysates were
two-fold-serial diluted for 5 dilutions and arrayed on nitrocellu-
lose-coated slides, probed with antibodies, and visualized by
diaminobenzidine colorimetric reaction. Relative protein levels for
each sample were determined by interpolation of each dilution
curves from the standard curve antibody slide. All the data points
were normalized for protein loading and transformed to linear
value. Linear values were transformed to Log2 value and then
median-centered for hierarchical cluster analysis. The heatmap
was generated in Cluster 3.0 as a hierarchical cluster using Pearson
Correlation and a center metric (additional details are provided is
Fig. S5).
Statistics
Statistical analysis of offspring genotype was calculated by the
Chi-squared test comparing observed and expected results. Data
from cellular assays, western blot, and qRT-PCR quantifications
was analyzed using the 2-tailed t-test. In both cases, significance
was defined as p#0.05.
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